Zhenjiang Zhao1,2, Guoguo Jin3, Yinghui Ge4,5, Zhiping Guo1,6,7. 1. People's Hospital of Zhengzhou University, Zhengzhou, 450000, Henan, China. 2. Department of Radiology, Luoyang Orthopedic Hospital of Henan Province, Zhengzhou, 450018, Henan, China. 3. Bone Tumor Research Office, Luoyang Orthopedic Hospital of Henan Province, Zhengzhou, 450018, Henan, China. 4. People's Hospital of Zhengzhou University, Zhengzhou, 450000, Henan, China. geyinghui74@sina.com. 5. Department of Radiology, Fuwai Central China Cardiovascular Hospital, Zhengzhou, 450000, Henan, China. geyinghui74@sina.com. 6. Henan Luoyang Orthopaedics Institute, Zhengzhou, 450018, Henan, China. 7. Fuwai Central China Cardiovascular Hospital, Zhengzhou, 450000, Henan, China.
Abstract
BACKGROUND: Naringenin, a flavonoid compound, has a wide variety of uses in the pharmaceutical industry for its antioxidant and anti-inflammatory potential. OBJECTIVES: The current experiment aimed to investigate the anticancer effect of naringenin in triple-negative human breast cancer cells (MDA-MR-231) and an animal model with 7,12-dimethylbenz[a] anthracene (DMBA)-induced breast cancer in female rats to determine the mechanisms and molecular targets. METHODS: The cytotoxic effects of naringenin against MDA-MB-231 cells were assessed by MTT assay. Apoptosis and cell cycle alterations were analyzed via flow cytometry. Morphological and biochemical changes in DMBA-induced cancer with naringenin treatment were assayed using our protocol. The potential mechanisms of action were verified via qRT-PCR. RESULTS: Naringenin was found to inhibit cell proliferation in a time- and concentration-dependent manner. This effect was associated with cell cycle arrest at the G0/G1 phase, along with apoptosis and deposition at the sub-G1 phase (75%). Treatment with naringenin reduced tumor incidence (45.55, 40, and 27.67%) and tumor burden (78.7, 35.4, and 1.2 g) in a dose-dependent manner. Naringenin treatment altered the biochemical and antioxidant parameters related to inflammation necessary for anticancer activity. The qRT-PCR studies further confirmed the mitochondrial-mediated apoptotic effects of naringenin. CONCLUSION: On the basis of these results, we can conclude that naringenin exerts an anticancer effect in the MDA-MB-231 cell line that arrests cell development at the G0/G1 phase, and in vivo it alters the mitochondrial-mediated intrinsic pathway responsible for apoptosis.
BACKGROUND: Naringenin, a flavonoid compound, has a wide variety of uses in the pharmaceutical industry for its antioxidant and anti-inflammatory potential. OBJECTIVES: The current experiment aimed to investigate the anticancer effect of naringenin in triple-negative human breast cancer cells (MDA-MR-231) and an animal model with 7,12-dimethylbenz[a] anthracene (DMBA)-induced breast cancer in female rats to determine the mechanisms and molecular targets. METHODS: The cytotoxic effects of naringenin against MDA-MB-231 cells were assessed by MTT assay. Apoptosis and cell cycle alterations were analyzed via flow cytometry. Morphological and biochemical changes in DMBA-induced cancer with naringenin treatment were assayed using our protocol. The potential mechanisms of action were verified via qRT-PCR. RESULTS: Naringenin was found to inhibit cell proliferation in a time- and concentration-dependent manner. This effect was associated with cell cycle arrest at the G0/G1 phase, along with apoptosis and deposition at the sub-G1 phase (75%). Treatment with naringenin reduced tumor incidence (45.55, 40, and 27.67%) and tumor burden (78.7, 35.4, and 1.2 g) in a dose-dependent manner. Naringenin treatment altered the biochemical and antioxidant parameters related to inflammation necessary for anticancer activity. The qRT-PCR studies further confirmed the mitochondrial-mediated apoptotic effects of naringenin. CONCLUSION: On the basis of these results, we can conclude that naringenin exerts an anticancer effect in the MDA-MB-231 cell line that arrests cell development at the G0/G1 phase, and in vivo it alters the mitochondrial-mediated intrinsic pathway responsible for apoptosis.
Entities:
Keywords:
Apoptosis; Breast cancer; Caspase-3; DMBA; Naringenin
Authors: P V Pradeep; Anjali Mishra; B N Mohanty; K C Mohapatra; Gaurav Agarwal; Saroj Kanta Mishra Journal: World J Surg Date: 2007-08 Impact factor: 3.352
Authors: Jesse S Boehm; Jean J Zhao; Jun Yao; So Young Kim; Ron Firestein; Ian F Dunn; Sarah K Sjostrom; Levi A Garraway; Stanislawa Weremowicz; Andrea L Richardson; Heidi Greulich; Carly J Stewart; Laura A Mulvey; Rhine R Shen; Lauren Ambrogio; Tomoko Hirozane-Kishikawa; David E Hill; Marc Vidal; Matthew Meyerson; Jennifer K Grenier; Greg Hinkle; David E Root; Thomas M Roberts; Eric S Lander; Kornelia Polyak; William C Hahn Journal: Cell Date: 2007-06-15 Impact factor: 41.582
Authors: Debajit K Biswas; Qian Shi; Shanon Baily; Ian Strickland; Sankar Ghosh; Arthur B Pardee; J Dirk Iglehart Journal: Proc Natl Acad Sci U S A Date: 2004-06-25 Impact factor: 11.205